U.S. Molecular Imaging Companies Leverage Technology Innovation and Design Modularity to Widen the Market Scope
May 3, 2017 | Frost & SullivanEstimated reading time: 3 minutes
The adoption of value-based reimbursement in the United States (U.S.) healthcare will make molecular imaging instrumental for quicker diagnosis, more accurate disease staging, and selection of targeted treatments. New radiopharmaceuticals for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are also driving adoption of molecular imaging equipment in wider clinical care. The market, however, faces several challenges, including growing competition from lower-cost modalities, such as computed tomography (CT), magnetic resonance imaging (MRI), and uncertainty of future supply of Tc-99m, a key SPECT radiopharmaceutical used for cardiac scans.
ThinkstockPhotos-179408284.jpgAnalysis of the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023 is part of Frost & Sullivan’s Advanced Medical Technologies Growth Partnership Service program. The analysis finds that the PET/CT equipment market will experience huge growth over the next few years, mainly due to the launch of novel technologies and quantitation software. This expansion will also benefit from the launch of modern PET radiopharmaceuticals in oncology, neurology, cardiology and other clinical areas. This combination of current technologies and recent radiopharmaceutical products will provide opportunities for companies to develop faster, safer and more accurate PET/CT scans using analytics, and advanced software based on newer quantification algorithms.
The SPECT/CT equipment market will grow to reach $75.6 million by 2023. The PET and SPECT radiopharmaceuticals markets will grow at a compound annual growth rate (CAGR) of 15.2 percent and 4.9 percent, respectively, from 2016 to 2023 to reach revenues of $675.8 million and $910.8 million.
“Molecular imaging is experiencing a renaissance with new products, improved quantitation software, and higher imaging quality, while the radiopharmaceuticals market is undergoing significant innovation that will broaden the scope of imaging beyond traditional cardiac and oncology applications. For instance, PET/CT and SPECT/CT platforms can eventually be used for early detection of diseases such as dementia, Alzheimer's and post-traumatic stress disorder,” said Transformational Health Senior Research Analyst Tanvir Jaikishen.
The PET/CT equipment market will continue to grow vastly the next few years with new technology, better quantitation algorithms and new PET radiopharmaceuticals in oncology, neurology and cardiology opening up new clinical areas. SPECT/CT on the other hand, will continue to experience declining revenues for the next few years, mostly due to uncertainty of future Tc-99m supply and challenges with SPECT quantitation accuracy. With cyclotron-based approaches towards manufacturing Tc-99m becoming commercially viable in the next two years, coupled with existing and future advances made to SPECT, quantitation accuracy, The SPECT/CT market is expected to grow by 2019.
The molecular imaging and radiopharmaceuticals markets, though concentrated, are highly competitive. Key participants, such as GE Healthcare, Siemens Healthineers, Philips Healthcare, Siemens PETNET, Toshiba America Medical Systems, NeuSoft, Bracco, and Lantheus Medical, must work with end users to reduce dosage and scan times, increase patient volumes, and improve workflow efficiencies. Partnership arrangements will help players capture a larger market share and become the go-to providers for all molecular imaging requirements.
Upcoming market disruptions and emerging growth opportunities include:
- Launch of cadmium zinc telluride (CZT) whole body SPECT that allows the use of multiple radiopharmaceuticals simultaneously. This eliminates the need for whole body scans and takes SPECT beyond cardiology, giving applicability in multiple clinical areas.
- Enhanced SPECT quantitation accuracy that has encouraged clinicians to recapture lost share of myocardial perfusion imaging from PET/CT.
- Novel radiopharmaceuticals, which will allow for more accurate staging and diagnosis of diseases, for example, Axumin by Blue Earth Diagnostics used for detection of recurrent prostate cancer.
- New PET and SPECT radiopharmaceuticals for neurology, orthopedics, and other clinical areas will increase the scope of molecular imaging. These radiopharmaceuticals will result in the reduced use of Tc-99m and fluorodeoxyglucose (FDG) for SPECT/CT and PET/CT scans respectively.
“Going forward, PET/CT vendors will focus on modularity of design and smaller footprint modalities to target smaller providers, such as imaging/radiology centers and small hospitals, and address end-user affordability issues. On the other side, SPECT/CT vendors will seek primarily to recapture the myocardial perfusion imaging market space from PET by offering a lower cost modality to hospitals and imaging centers as well as an inexpensive& scan to payors, without compromise on quality and accuracy,” added Jaikishen.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.
Suggested Items
LQDX Divests Aluminum Soldering Business - Mina™ - to Taiyo America Inc.
05/02/2024 | PRNewswireLQDX, formerly known as Averatek Corp., developer of high-performance materials for advanced semiconductor manufacturing, today announced that it has divested its aluminum soldering business – known as MinaTM – to Taiyo America Inc., a global market leader in advanced electronic materials.
IDTechEx Report on Quantum Technology: Nano-scale Physics for Massive Market Impact
04/30/2024 | PRNewswireThe quantum technology market leverages nano-scale physics to create revolutionary new devices for computing, sensing, and communications. Across the industry, quantum technology offers a paradigm shift in performance compared with incumbent solutions.
Guerrilla RF Completes Strategic Acquisition of GaN Device Portfolio from Gallium Semiconductor
04/29/2024 | BUSINESS WIREGuerrilla RF, Inc. has finalized the acquisition of Gallium Semiconductor's entire portfolio of GaN power amplifiers and front-end modules. Effective April 26th, 2024, GUER acquired all previously released components as well as new cores under development at Gallium Semiconductor.
Amphenol Reports Q1 2024 Results, Announces New Stock Repurchase Program
04/26/2024 | BUSINESS WIREAmphenol Corporation reported first quarter 2024 results. In addition, the Company is announcing a new three-year, $2 billion stock repurchase program.
Chinese Smartphone Market Maintains its Recovery Momentum at 6.5% Growth in 1Q24,
04/26/2024 | IDCAccording to preliminary data from the International Data Corporation (IDC) Worldwide Quarterly Mobile Phone Tracker, China smartphone shipments grew 6.5% year over year (YoY) to 69.3 million units in 1Q24.